| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
12,329 |
11,578 |
$102K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
8,073 |
7,502 |
$47K |
| J0585 |
Injection, onabotulinumtoxina, 1 unit |
252 |
252 |
$45K |
| 52442 |
|
456 |
455 |
$21K |
| 51798 |
|
10,771 |
9,834 |
$18K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
4,066 |
4,028 |
$17K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
1,655 |
1,628 |
$15K |
| J0897 |
Injection, denosumab, 1 mg |
50 |
48 |
$13K |
| 52441 |
|
455 |
455 |
$12K |
| 52287 |
|
293 |
292 |
$12K |
| 52000 |
|
2,361 |
2,346 |
$11K |
| 51703 |
|
1,062 |
885 |
$9K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
1,652 |
1,626 |
$6K |
| 51710 |
|
438 |
372 |
$6K |
| 87481 |
|
1,650 |
1,624 |
$6K |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
2,189 |
1,978 |
$4K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,568 |
1,332 |
$3K |
| 51728 |
|
567 |
562 |
$2K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
264 |
125 |
$2K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
55 |
55 |
$1K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,659 |
1,622 |
$1K |
| 87640 |
|
1,654 |
1,627 |
$1K |
| 87500 |
|
1,651 |
1,625 |
$1K |
| 87641 |
|
1,651 |
1,626 |
$1K |
| 87653 |
|
1,664 |
1,625 |
$1K |
| 52281 |
|
60 |
60 |
$1K |
| 81000 |
|
3,783 |
3,704 |
$774.47 |
| J9217 |
Leuprolide acetate (for depot suspension), 7.5 mg |
13 |
13 |
$744.81 |
| 99490 |
Ccm add 20min |
69 |
69 |
$698.78 |
| 64566 |
|
641 |
340 |
$662.08 |
| 88108 |
|
1,442 |
1,233 |
$637.25 |
| 99205 |
Prolong outpt/office vis |
379 |
378 |
$514.41 |
| 51741 |
|
763 |
746 |
$419.02 |
| J1580 |
Injection, garamycin, gentamicin, up to 80 mg |
114 |
105 |
$345.58 |
| 99245 |
|
78 |
78 |
$336.66 |
| 99244 |
Office or other outpatient consultation, moderate to high complexity |
21 |
21 |
$190.51 |
| 99439 |
|
14 |
14 |
$136.26 |
| J1071 |
Injection, testosterone cypionate, 1 mg |
187 |
124 |
$95.17 |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
111 |
110 |
$75.00 |
| 99426 |
|
39 |
39 |
$48.24 |
| 88313 |
|
1,442 |
1,233 |
$34.93 |
| 51705 |
|
14 |
13 |
$25.28 |
| 96402 |
|
25 |
25 |
$9.71 |
| 86328 |
|
262 |
261 |
$0.00 |
| 55700 |
|
13 |
13 |
$0.00 |
| 93980 |
|
12 |
12 |
$0.00 |
| 76942 |
|
13 |
13 |
$0.00 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
110 |
109 |
$0.00 |
| 76872 |
|
27 |
27 |
$0.00 |
| 99024 |
|
38 |
36 |
$0.00 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
59 |
59 |
$0.00 |
| 54235 |
|
12 |
12 |
$0.00 |